Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000887811 | SCV001031397 | benign | Familial hemophagocytic lymphohistiocytosis 2 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000887811 | SCV001260918 | uncertain significance | Familial hemophagocytic lymphohistiocytosis 2 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Institute for Clinical Genetics, |
RCV001358428 | SCV002009737 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002264049 | SCV002542354 | uncertain significance | Autoinflammatory syndrome | 2020-05-01 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001358428 | SCV004126686 | likely benign | not provided | 2022-10-01 | criteria provided, single submitter | clinical testing | PRF1: BP4, BP7 |
Department of Pathology and Laboratory Medicine, |
RCV001358428 | SCV001554157 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The PRF1 p.Gln540Gln variant was identified in one homozygous individual with multiple sclerosis and one heterozygous individual with familial hemophagocytic lymphohistiocytosis (Cappellano_2008_PMID:18496551, Liu_2015_PMID:26274329). The variant was identified in dbSNP (ID: rs149776121), ClinVar (classified as benign by Invitae) and LOVD 3.0 (variant effect not shared), but was not identified in Cosmic. The variant was identified in control databases in 499 of 268182 chromosomes (1 homozygous) at a frequency of 0.001861 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1, non-cancer). The variant was observed in the following populations: East Asian in 245 of 19248 chromosomes (freq: 0.01273), European (Finnish) in 81 of 25022 chromosomes (freq: 0.003237), South Asian in 76 of 30526 chromosomes (freq: 0.00249), Other in 11 of 6702 chromosomes (freq: 0.001641), European (non-Finnish) in 76 of 118130 chromosomes (freq: 0.000643), Latino in 6 of 35106 chromosomes (freq: 0.000171), African in 3 of 23586 chromosomes (freq: 0.000127) and Ashkenazi Jewish in 1 of 9862 chromosomes (freq: 0.000101). The p.Gln540Gln variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, 4 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing and the creation of a new 3' splice site. However, this has not been confirmed by RNA analysis and is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |